Our Timeline
C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform: C-Path announced that the European Medicines Agency (EMA) has issued a letter of support for the Duchenne Regulatory Science Consortium’s (D-RSC) Model-based Clinical Trial Simulation Platform for Duchenne Muscular Dystrophy (DMD).
C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System: C-Path announced that its Transplant Therapeutics Consortium (TTC) received a qualification opinion for the iBox Scoring System as a secondary efficacy endpoint in clinical trials investigating novel immunosuppressive medicines in kidney transplant patients.
C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform: C-Path announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).
‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases: A new initiative to boost research and development into rare and paediatric diseases will launch today [Thursday 8 December] at the European Health Summit.
C-Path Receives Data Transfer from Network of Hospitals in Japan: C-Path received properly anonymized electronic patient record (EPR) data from three hospitals in the Neonatal Research Network of Japan — Nagano Children’s Hospital, Kyorin University and Osaka General Hospital.
FDA Expands Support of C-Path CDRC to Automate EHR Data Extraction: C-Path’s CURE Drug Repurposing Collaboratory (CDRC) has received additional funds as part of a new U.S. Food and Drug Administration (FDA) Health and Human Services (HHS) grant.
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases: C-Path announced that it has recently launched a pre-consortium collaboration with the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER), focused on accelerating medical product development in alpha-1 antitrypsin deficiency (AATD). The FDA announced the pre-consortium today in a statement on its website.
C-Path Awarded FDA Grant to Establish Public-Private Partnership to Advance Treatments for Rare Neurodegenerative Diseases: C-Path announced it will serve as the convener of the Critical Path for Rare Neurodegenerative Diseases (CP-RND), a new public-private partnership (PPP) to benefit people across multiple rare neurodegenerative diseases, supported by a grant from the U.S. Food and Drug Administration (FDA). The Agency announced the PPP today in a press release.
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Lysosomal Diseases: C-Path announced the launch of a pre-consortium collaboration focused on accelerating medical product development in lysosomal diseases, supported by a grant from the U.S. Food and Drug Administration (FDA).
C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation: C-path announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. (RCT) that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator (TRxA).
C-Path Receives Largest Data Transfer to Date from UK’s National Neonatal Research Database: C-Path received fully anonymized electronic patient record (EPR) data from the National Neonatal Research Database (NNRD).
C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative: C-Path’s Type 1 Diabetes Consortium (T1DC) announced that the European Medicines Agency (EMA) has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials.
C-Path European Nonprofit Established in Amsterdam: C-Path is excited to announce the opening of its EU nonprofit headquarters in the Netherlands, which will focus on the development of existing and future activities in Europe.
C-Path launches Type 1 Diabetes (T1D) Consortium
C-Path collaborates with FDA’s CDER and FNIH’s Biomarker Consortium in drafting a “Framework for Defining Evidentiary Criteria for Biomarker Qualification”
C‐Path receives approval from the European Medicines Agency (EMA) for imaging biomarker as a qualified measure to select patients with early stage cognitive impairment for Alzheimer’s disease clinical trials.
With support and funding from the Polycystic Kidney Disease Foundation, C‐Path launches Polycystic Kidney Disease Outcome Consortium (PKDOC).
C‐Path launches Critical Path to TB Drug Regimens (CPTR).
C‐Path launches Coalition Against Major Diseases (CAMD) as a consortium with pharmaceutical companies, patient groups, FDA and NIH to address clinical trial needs in neurological diseases.
Arizona’s Governor Janet Napolitano honors C‐Path with an “Arizona Innovation Award” to recognize its groundbreaking approach to speeding the development of safe, innovative medicines and medical devices.
President George W. Bush signs bill that authorizes FDA to create “Critical Path Public/Private Partnerships.” The first (and most successful) of these is the collaboration between the FDA and C‐Path.
C‐Path hosts ribbon‐cutting ceremony at the Library of Congress to officially announce opening of its Rockville, Maryland office.
C‐Path hosts Tucson ribbon‐cutting ceremony to officially launch institute.
C‐Path begins first fiscal year with six full‐time employees.
State of Arizona awards C-Path a planning grant. C-Path files articles of non-profit incorporation.
